{"id":21,"date":"2021-08-17T15:22:27","date_gmt":"2021-08-17T15:22:27","guid":{"rendered":"https:\/\/springwrks.wpengine.com\/?page_id=21"},"modified":"2025-08-26T15:46:17","modified_gmt":"2025-08-26T15:46:17","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/springworkstx.com\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"

[vc_row row_padding_top=”pt-1″ row_padding_bottom=”pb-1″ content_placement=”middle” el_class=”overlap-above-column”][vc_column column_padding_top=”pt-5″ column_padding_bottom=”pb-5″ width=”1\/2″ el_class=”overlap-above-column”]

Pipeline<\/h1><\/div>[vc_column_text]<\/p>\n

We measure ourselves by the impact we have on people with cancer.
\nLet\u2019s go big.<\/span><\/h1>\n

[\/vc_column_text][\/vc_column][vc_column column_padding_top=”pt-0″ column_padding_bottom=”pb-0″ width=”1\/2″]

\n \n \n \n \n <\/mask>\n <\/defs>\n \n <\/svg>\n <\/div>\n\n [\/vc_column][\/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1676997737351{background-image: url(https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/09\/Untitled-design-58.png?id=508) !important;}” el_class=”overflow-visible”][vc_column] \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
\n \n \n \n
<\/h3><\/th>\n Preclinical<\/th>\n Phase 1<\/th>\n Phase 2<\/th>\n Phase 3<\/th>\n Regulatory Submission<\/th>\n Approved<\/th>\n Collaborators<\/th>\n <\/tr>\n <\/thead>\n <\/table>\n <\/div>\n <\/div>\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n

Nirogacestat (Gamma Secretase Inhibitor)<\/h3>\n <\/td>\n <\/tr>\n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Adult desmoid tumors<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n Approved in the U.S. and E.U.<\/span>\n
<\/div>\n <\/div>\n <\/td>\n <\/td>\n <\/tr>\n
\n
\n

<\/h4>\n Approved in the U.S. and E.U. for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. <\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Pediatric desmoid tumors<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n \"\"<\/td>\n <\/tr>\n
\n
\n

<\/h4>\n In collaboration with Children\u2019s Oncology Group (COG), a Phase 2 clinical trial is evaluating nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Ovarian Granulosa Cell Tumors \u00b9<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n <\/td>\n <\/tr>\n
\n
\n

<\/h4>\n Ovarian granulosa cell tumors are a rare ovarian cancer subtype for which there are currently no FDA-approved therapies. SpringWorks is conducting a Phase 2 study of nirogacestat in recurrent ovarian granulosa cell tumors.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n
\n <\/i><\/a>\n

+ BCMA-Targeting Agents<\/h4>\n

Relapsed\/refractory multiple myeloma<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n \"The<\/td>\n <\/tr>\n
\n
\n

<\/h4>\n SpringWorks is evaluating nirogacestat as a potential treatment for patients with multiple myeloma as part of several B-cell maturation agent (BCMA) combination therapy regimens in collaboration with industry leaders.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n

Mirdametinib (MEK Inhibitor)<\/h3>\n <\/td>\n <\/tr>\n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Adult and pediatric NF1-associated plexiform neurofibromas<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n Approved in the U.S. and E.U.<\/span>\n
<\/div>\n <\/div>\n <\/td>\n <\/td>\n <\/tr>\n
\n
\n

<\/h4>\n Approved by the US FDA for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. Conditionally approved by the European Commission for the treatment of symptomatic, inoperable PN in pediatric and adult patients with NF1 aged 2 years and above.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Pediatric low-grade gliomas<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n \"\"<\/td>\n <\/tr>\n
\n
\n

<\/h4>\n In collaboration with St. Jude Children\u2019s Research Hospital, a Phase 2 clinical trial is evaluating mirdametinib in children, adolescents, and young adults with low-grade glioma.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n

SW-682 (TEAD Inhibitor)<\/h3>\n <\/td>\n <\/tr>\n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Hippo mutant tumors<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n <\/td>\n <\/tr>\n
\n
\n

<\/h4>\n SpringWorks is developing SW-682 , a novel small molecule inhibitor of the TEA Domain (TEAD) family of transcription factors, for the potential treatment of biomarker-defined solid tumors driven by Hippo pathway mutations.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n \n

\n

SW-3431 (PP2A Activator)<\/h3>\n <\/td>\n <\/tr>\n

\n
\n <\/i><\/a>\n

Monotherapy<\/h4>\n

Rare Uterine Cancers<\/p>\n <\/div>\n <\/th>\n

\n\n\n\n
\n
<\/div>\n <\/div>\n <\/td>\n <\/td>\n <\/tr>\n
\n
\n

<\/h4>\n SW-3431 is a first-in-class small molecule activator of specific Protein Phosphatase 2A (PP2A) complexes in preclinical development. PP2A mutations represent a class of targetable oncogenic drivers in molecularly defined subsets of uterine cancer patients with high unmet need.<\/div>\n <\/div>\n <\/td>\n <\/tr>\n\n\n <\/tbody>\n <\/table>\n <\/div>\n <\/div>\n
\n

<\/h3>\n
\n

Nirogacestat (Gamma Secretase Inhibitor)<\/h3>\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Adult desmoid tumors<\/p>\n

Regulatory Approval<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n

<\/h4>\n
Approved in the U.S. and E.U. for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Pediatric desmoid tumors<\/p>\n

Phase 2 In Progress:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n
\n

Collaborators:<\/p>\n <\/div>\n

\n \"\" <\/div>\n\n <\/div>\n
\n

<\/h4>\n
In collaboration with Children\u2019s Oncology Group (COG), a Phase 2 clinical trial is evaluating nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Ovarian Granulosa Cell Tumors \u00b9<\/p>\n

Phase 2 In Progress:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n

<\/h4>\n
Ovarian granulosa cell tumors are a rare ovarian cancer subtype for which there are currently no FDA-approved therapies. SpringWorks is conducting a Phase 2 study of nirogacestat in recurrent ovarian granulosa cell tumors.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n <\/i>\n <\/a>\n

+ BCMA-Targeting Agents<\/h4>\n

Relapsed\/refractory multiple myeloma<\/p>\n

Phase 2 In Progress:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n
\n

Collaborators:<\/p>\n <\/div>\n

\n \"The <\/div>\n\n <\/div>\n
\n

<\/h4>\n
SpringWorks is evaluating nirogacestat as a potential treatment for patients with multiple myeloma as part of several B-cell maturation agent (BCMA) combination therapy regimens in collaboration with industry leaders.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n

Mirdametinib (MEK Inhibitor)<\/h3>\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Adult and pediatric NF1-associated plexiform neurofibromas<\/p>\n

Regulatory Approval<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n

<\/h4>\n
Approved by the US FDA for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. Conditionally approved by the European Commission for the treatment of symptomatic, inoperable PN in pediatric and adult patients with NF1 aged 2 years and above.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Pediatric low-grade gliomas<\/p>\n

Phase 2 In Progress:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n
\n

Collaborators:<\/p>\n <\/div>\n

\n \"\" <\/div>\n\n <\/div>\n
\n

<\/h4>\n
In collaboration with St. Jude Children\u2019s Research Hospital, a Phase 2 clinical trial is evaluating mirdametinib in children, adolescents, and young adults with low-grade glioma.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n

SW-682 (TEAD Inhibitor)<\/h3>\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Hippo mutant tumors<\/p>\n

Phase 1 In Progress:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n

<\/h4>\n
SpringWorks is developing SW-682 , a novel small molecule inhibitor of the TEA Domain (TEAD) family of transcription factors, for the potential treatment of biomarker-defined solid tumors driven by Hippo pathway mutations.<\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n

SW-3431 (PP2A Activator)<\/h3>\n
\n \n <\/i>\n <\/a>\n

Monotherapy<\/h4>\n

Rare Uterine Cancers<\/p>\n

Pre-Clinical:<\/p>\n

\n
\n\n
\n <\/div>\n <\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n
\n

<\/h4>\n
SW-3431 is a first-in-class small molecule activator of specific Protein Phosphatase 2A (PP2A) complexes in preclinical development. PP2A mutations represent a class of targetable oncogenic drivers in molecularly defined subsets of uterine cancer patients with high unmet need.<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>[vc_column_text css=”.vc_custom_1747241065436{padding-top: 16px !important;padding-right: 16px !important;padding-bottom: 16px !important;padding-left: 16px !important;background-color: #ffffff !important;}”]<\/p>\n

(1) Results from Phase 2 trial were submitted to a peer-reviewed journal in April 2025; publication is expected by year-end. (2) Includes preclinical, Phase 1, and Phase 2 studies planned or ongoing with GSK, Janssen, Pfizer, and Regeneron. On June 6, 2024, GSK notified SpringWorks that it is terminating the collaboration agreement and winding down the study; no further enrollment is expected, though the study will continue for the patients enrolled at the time of termination notice.<\/small><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_padding_top=”pt-0″ row_padding_bottom=”pb-2″ column_padding=”col-padding-none” full_width=”stretch_row” equal_height=”yes” content_placement=”middle”][vc_column col_padding_left=”pl-0″][\/vc_column][\/vc_row][vc_row row_style=”split-row” column_padding=”col-padding-none” full_width=”stretch_row_content” equal_height=”yes” content_placement=”middle”][vc_column col_padding_left=”pl-0″ width=”1\/2″ css=”.vc_custom_1635192526256{background-image: url(https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/10\/47YOr8LQ.jpeg?id=1118) !important;}”][\/vc_column][vc_column width=”1\/2″]

Our pipeline<\/h2><\/div>[vc_column_text]SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies. Our development programs include late-stage rare oncology programs as well as multiple programs addressing highly prevalent, genetically defined cancers. Our team is working with urgency on behalf of the patients living with these devastating illnesses.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row”][vc_column]

Let\u2019s unlock the future of targeted oncology<\/h2><\/div>[vc_column_text]<\/p>\n

We are meticulous about the science and passionate about its possibilities. This leads us to dig deeper \u2013 to explore the full potential of our molecules. You can see that approach in our pipeline. We have a diversified targeted oncology portfolio that includes standalone and combination therapies across various stages of development, including late-stage clinical trials in rare tumor types and multiple programs addressing highly prevalent, genetically defined cancers.<\/span><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row row_padding_top=”pt-1″ row_padding_bottom=”pb-1″ content_placement=”middle” el_class=”overlap-above-column”][vc_column column_padding_top=”pt-5″ column_padding_bottom=”pb-5″ width=”1\/2″ el_class=”overlap-above-column”][vc_column_text] We measure ourselves by the impact we have on people with cancer. Let\u2019s go big. [\/vc_column_text][\/vc_column][vc_column column_padding_top=”pt-0″ column_padding_bottom=”pb-0″ width=”1\/2″][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1676997737351{background-image: url(https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/09\/Untitled-design-58.png?id=508) !important;}” el_class=”overflow-visible”][vc_column][vc_column_text css=”.vc_custom_1747241065436{padding-top: 16px !important;padding-right: 16px !important;padding-bottom: 16px !important;padding-left: 16px !important;background-color: #ffffff !important;}”] (1) Results from Phase 2 trial were submitted to a peer-reviewed<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-21","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nRare Oncology Treatment Pipeline - SpringWorks Therapeutics<\/title>\n<meta name=\"description\" content=\"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/springworkstx.com\/pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline\" \/>\n<meta property=\"og:description\" content=\"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/springworkstx.com\/pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Springworks\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T15:46:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/08\/Screen-Shot-2021-08-17-at-9.33.04-AM-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"235\" \/>\n\t<meta property=\"og:image:height\" content=\"61\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@SpringWorksTx\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/springworkstx.com\\\/pipeline\\\/\",\"url\":\"https:\\\/\\\/springworkstx.com\\\/pipeline\\\/\",\"name\":\"Rare Oncology Treatment Pipeline - SpringWorks Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#website\"},\"datePublished\":\"2021-08-17T15:22:27+00:00\",\"dateModified\":\"2025-08-26T15:46:17+00:00\",\"description\":\"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/springworkstx.com\\\/pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/springworkstx.com\\\/pipeline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/springworkstx.com\\\/pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/springworkstx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#website\",\"url\":\"https:\\\/\\\/springworkstx.com\\\/\",\"name\":\"https:\\\/\\\/springworkstx.com\\\/\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#organization\"},\"alternateName\":\"https:\\\/\\\/springworkstx.com\\\/\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/springworkstx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#organization\",\"name\":\"SpringWorks Therapeutics\",\"alternateName\":\"SWTX\",\"url\":\"https:\\\/\\\/springworkstx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/springworkstx.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/Screen-Shot-2021-08-17-at-9.33.04-AM.png\",\"contentUrl\":\"https:\\\/\\\/springworkstx.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/Screen-Shot-2021-08-17-at-9.33.04-AM.png\",\"width\":235,\"height\":61,\"caption\":\"SpringWorks Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/springworkstx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/SpringWorksTx\"],\"description\":\"SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"201\",\"maxValue\":\"500\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Oncology Treatment Pipeline - SpringWorks Therapeutics","description":"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/springworkstx.com\/pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Pipeline","og_description":"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.","og_url":"https:\/\/springworkstx.com\/pipeline\/","og_site_name":"Springworks","article_modified_time":"2025-08-26T15:46:17+00:00","og_image":[{"width":235,"height":61,"url":"https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/08\/Screen-Shot-2021-08-17-at-9.33.04-AM-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@SpringWorksTx","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/springworkstx.com\/pipeline\/","url":"https:\/\/springworkstx.com\/pipeline\/","name":"Rare Oncology Treatment Pipeline - SpringWorks Therapeutics","isPartOf":{"@id":"https:\/\/springworkstx.com\/#website"},"datePublished":"2021-08-17T15:22:27+00:00","dateModified":"2025-08-26T15:46:17+00:00","description":"SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies.","breadcrumb":{"@id":"https:\/\/springworkstx.com\/pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/springworkstx.com\/pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/springworkstx.com\/pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/springworkstx.com\/"},{"@type":"ListItem","position":2,"name":"Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/springworkstx.com\/#website","url":"https:\/\/springworkstx.com\/","name":"https:\/\/springworkstx.com\/","description":"","publisher":{"@id":"https:\/\/springworkstx.com\/#organization"},"alternateName":"https:\/\/springworkstx.com\/","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/springworkstx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/springworkstx.com\/#organization","name":"SpringWorks Therapeutics","alternateName":"SWTX","url":"https:\/\/springworkstx.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/springworkstx.com\/#\/schema\/logo\/image\/","url":"https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/08\/Screen-Shot-2021-08-17-at-9.33.04-AM.png","contentUrl":"https:\/\/springworkstx.com\/wp-content\/uploads\/2021\/08\/Screen-Shot-2021-08-17-at-9.33.04-AM.png","width":235,"height":61,"caption":"SpringWorks Therapeutics"},"image":{"@id":"https:\/\/springworkstx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/SpringWorksTx"],"description":"SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"201","maxValue":"500"}}]}},"_links":{"self":[{"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/pages\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/comments?post=21"}],"version-history":[{"count":0,"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/pages\/21\/revisions"}],"wp:attachment":[{"href":"https:\/\/springworkstx.com\/wp-json\/wp\/v2\/media?parent=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}